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Abstract 
Positive allosteric modulators (PAMs) that target the M1 muscarinic acetylcholine (ACh) 
receptor (M1 mAChR) are potential treatments for cognitive deficits in conditions such as 
Alzheimer’s disease and schizophrenia. We recently reported novel 4-phenylpyridine-2-one 
and 6-phenylpyrimidin-4-one M1 mAChR PAMs with the potential to display different 
modes of positive allosteric modulation and/or agonism (Mistry et al., 2016), but their 
molecular mechanisms of action remain undetermined. The current study compared the 
pharmacology of three such novel PAMs with the prototypical first-generation PAM, BQCA, 
in a recombinant Chinese hamster ovary (CHO) cell line stably expressing the human M1 
mAChR. Interactions between the orthosteric agonists and the novel PAMs or BQCA 
suggested their allosteric effects were solely governed by modulation of agonist affinity. The 
greatest degree of positive co-operativity was observed with higher efficacy agonists, 
whereas minimal potentiation was observed when the modulators were tested against the 
lower efficacy agonist, xanomeline. Each PAM was investigated for its effects on the 
endogenous agonist, ACh, on three different signalling pathways, (ERK1/2 phosphorylation, 
IP1 accumulation and β-arrestin-2 recruitment), revealing that the allosteric potentiation 
generally tracked with the efficiency of stimulus-response coupling and that there was little 
pathway bias in the allosteric effects. Thus, despite the identification of novel allosteric 
scaffolds targeting the M1 mAChR, the molecular mechanism of action of these compounds 
is largely consistent with a model of allostery previously described for BQCA, suggesting 
that this may be a more generalized mechanism for M1 mAChR PAM effects than previously 
appreciated.  
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Introduction 
The muscarinic acetylcholine receptors (mAChRs) belong to the rhodopsin-like (Class A) 
family of G protein-coupled receptors (GPCRs). Five distinct mAChR subtypes (denoted M1-
M5) exist and exhibit a widespread distribution throughout the central nervous system (CNS) 
and peripheral organs (Caulfield 1993; Nathanson 2008; Kruse et al., 2014). The M1, M3 and 
M5 mAChRs preferentially couple to Gq/11 proteins, whereas the M2 and M4 mAChRs 
preferentially couple to Gi/o proteins. However, an ever-growing array of additional signalling 
pathways, including those not necessarily mediated by G proteins, has also been linked to 
mAChR activation (Lanzafame et al., 2003). 
 
The M1 mAChR is highly expressed in the cerebral cortex, hippocampus, striatum and 
thalamus (Cortés et al., 1986; 1987; Elhert and Tran, 1990); regions vital for memory, 
cognitive and locomotor functions. Therefore, the M1 mAChR has long been implicated in 
learning and memory, and remains a potential target for the treatment of Alzheimer’s disease 
and schizophrenia (Caulfield 1993; Langmead et al., 2008). A role for the M1 mAChR in 
treating the cognitive impairment in both of these diseases is further supported by the 
decrease in M1 mAChR expression in the pre-frontal cortex in brains from schizophrenic 
patients (Melancon et al., 2013; Conn et al., 2009). Improved cognition, learning and memory 
were observed in preclinical studies using the M1/M4-preferring orthosteric agonist, 
xanomeline (Xan), which were attenuated in M1 mAChR knockout (KO) mice (Bymaster et 
al., 2003), whereas memory deficits have been observed upon administration of mAChR 
antagonists or M1 mAChR KO in mice (Sauerberg et al., 1992; Wess 2004; Davie et al., 
2014). Importantly, Xan demonstrated clinical efficacy, particularly in treating psychosis and 
cognitive decline in clinical trials of Alzheimer’s disease and schizophrenia. Despite this, 
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Xan was not pursued further due to unacceptable off-target effects, largely attributed to a lack 
of mAChR subtype selectivity (Bodick et al., 1997; Shekar et al., 2008). 
 
Encouragingly, the mAChRs possess spatially distinct allosteric sites, which can be 
selectively targeted (Kruse et al., 2013; 2014). Recently, benzyl quinolone carboxylic acid 
(BQCA) was described as the first highly selective positive allosteric modulator (PAM) of 
the M1 mAChR, with preclinical efficacy in animal models of cognition (Ma et al., 2009) and 
has served as a major impetus for new discovery efforts (Kruse et al., 2014). However, 
significant challenges and unanswered questions remain regarding the optimal type of 
allosteric ligand for successful progression through preclinical studies to man. For instance, 
allosteric modulators can display complex behaviours such as “probe dependence”, where the 
magnitude and direction of an allosteric effect for the modulator can change depending on 
which orthosteric ligand is used as a probe for receptor function (Kenakin 2005). Another 
example is “biased modulation”; the ability of different allosteric ligands to engender unique 
receptor conformations, whereby certain signalling pathways are differentially modulated 
relative to others (Kenakin and Christopoulos 2013; Christopoulos 2014). 
 
The simplest mechanism that explains allostery is the classic Monod-Wyman-Changeux 
(MWC) model (Monod et al., 1965), which predicts that probe dependence arises as a 
function of the efficacy of the orthosteric ligand, and that biased modulation cannot occur 
without the existence of additional active states (Canals et al., 2011; Changeux and 
Christopoulos 2016). A characterization of BQCA at the M1 mAChR revealed that BQCA 
indeed behaves in a manner generally consistent with a two-state MWC mechanism (Canals 
et al., 2012; Ehlert and Griffin, 2014). However, this is not always the case with other 
mAChR modulators (e.g. Valant et al., 2012), and thus detailed molecular pharmacological 
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characterisation is a necessary first step in understanding the mechanism of action of any new 
allosteric ligands. Although BQCA was a major breakthrough in terms of proof of concept, it 
possesses a very low affinity for the receptor, and additional liabilities that precluded it from 
further clinical development (Canals et al., 2011; Davoren et al., 2016). Thus, there remains 
an ongoing need for the discovery of new M1 mAChR PAMs. 
 
Our laboratory recently identified a series of novel M1 mAChR PAMs with 4-
phenylpyridine-2-one and 6-phenylpyrimidin-one scaffolds that are distinct from BQCA 
(Mistry et al., 2016). However, a detailed mechanistic evaluation of their pharmacological 
properties has not been undertaken. Thus, the aim of this study was to characterise exemplar 
molecules from this series of PAMs and compare their behaviours to BQCA, particularly 
with regards to mechanisms underlying probe dependence and the potential for biased 
modulation. We found that, despite possessing a chemically distinct scaffold, the novel 
PAMs generally behave in a manner akin to that of BQCA. 
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Materials and Methods 
Materials:  Dulbecco’s Modified Eagle Medium (DMEM) and FlpIn Chinese hamster ovary 
(CHO) cells were purchased from Invitrogen (Carlsbad, CA, USA). Fetal bovine serum was 
purchased from ThermoTrace (Melbourne, VIC, Australia). The IP-One assay kit and 
reagents were purchased from Cisbio (Codolet, France). [
3
H]-NMS (70.0 Ci/mmol) and 
AlphaScreen
TM
 protein A IgG beads were purchased from Perkin Elmer Life and Analytical 
Sciences (Waltham, MA, USA). The Sure-Fire
TM
 cellular ERK1/2 assay kits were a generous 
gift from TGR BioSciences (Adelaide, Australia). Polyethyleneimine (PEI, molecular mass, 
25kDa) was from Polysciences (Warrington, PA). 1-(4-Methoxybenzyl)-4-oxo-1,4-
dihydroquinoline-3-carboxylic acid (benzyl quinolone carboxylic acid; BQCA), 4-(2-((4-
(1H-pyrazol-4-yl)benzyl)oxy)phenyl)-1-(2-hydroxycyclohexyl)pyridin-2(1H)-one 
(MIPS1674), 1-(2-hydroxycyclohexyl)-4-(2-((6-(1-methyl-1H-pyrazol-4-yl)-pyridin-3-
yl)methoxy)phenyl)pyridin-2(1H)-one (MIPS1745), and 3-(2-hydroxycyclohexyl)-6-(2-((4-
(1-methyl-1H-pyrazol-4-yl)- benzyl)oxy)phenyl)pyrimidin-4(3H)-one (MIPS1780) were 
synthesized in house (Mistry et al. 2016). Xanomeline was a generous gift from Dr. Christian 
Felder (Eli Lilly, USA). Coelenterazine h was purchased from Nanolight Technologies 
(Pinetop, AZ, USA). The YFP--arrestin-2 construct was a gift from Dr. Marc Caron (Duke 
University). The M1-Rluc8 constructs were generated in-house as described previously 
(Yeatman et al. 2014). All other chemicals were purchased from Sigma-Aldrich (St Louis, 
MO). 
 
Cell culture:  FlpInCHO cells stably expressing the wild type human muscarinic 
acetylcholine M1 receptor (hM1 mAChR; 37031±3397 sites/cell) (Mistry et al., 2016) were 
grown in DMEM (supplemented with 5% FBS), and were used for the IP1 accumulation and 
ERK1/2 signaling assays. For the -arrestin-2 recruitment assays, 3x106 parental FlpInCHO 
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cells were transiently transfected with 0.6g of M1-Renilla luciferase (Rluc)-8, 1.8g of 
YFP--arrestin-2 and 3.6g of empty pcDNA vector in a 100mM dish, using linear 
polyethyleneimine (PEI:DNA ratio 6:1) diluted in NaCl (150mM).  DNA:PEI complexes 
were formed by incubation at room temperature for 15 min, then added to the cells and 
incubated at 37°C for 24h. Transfected cells were replated into white CulturPlates (Perkin 
Elmer) and incubated for a further 24h prior to use in signalling assays. 
 
IP1 accumulation assay:  The IP-one assay kit (Cisbio, France) was used for the quantitative 
measurement of myo-inositol 1 phosphate (IP1). 10,000 cells/well were seeded into 96 well 
plates and incubated overnight at 37°C.  The following day, cells were pre-incubated with IP1 
stimulation buffer (10mM HEPES, 1mM CaCl2, 0.5mM MgCl2, 4.2mM KCl, 146mM NaCl, 
5.5mM D-glucose, 50mM LiCl, pH 7.4) for 1h at 37°C.  Orthosteric and allosteric ligands 
were added and incubated for a further 1h at 37°C.  Cells were lysed in lysis buffer (50mM 
HEPES-NaOH pH 7.0, 15mM KF, 1.5% (v/v) Triton-X-100) and 14L of cell lysates were 
transferred into 384-well Optiplates (PerkinELmer Life Sciences). An IP1 standard curve was 
prepared and added to the Optiplates in parallel.  Homogenous time resolved FRET (HTRF) 
reagents (cryptate-labeled anti-IP1 antibody, the d2-labeled IP1 analogue; diluted 1:20 in lysis 
buffer) were added and plates were incubated for 1h at 37°C.  Samples were excited at 
340nm and emission was captured at 590 and 665 nm using the Envision multi-label plate 
reader (PerkinElmer Life Sciences). IP1 concentrations were interpolated from the standard 
curve using HTRF ratio values, and responses were normalized to the maximum response 
elucidated by ACh. 
 
Receptor alkylation studies in IP1 accumulation experiments:  10,000 cells/well were seeded 
into poly-D-lysine coated 96-well plates. Following the initial 1h incubation in IP1 
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stimulation buffer, cells were pre-treated for 30 min at 37°C with varying concentrations of 
the irreversible orthosteric-site alkylating agent, phenoxybenzamine (PBZ) or vehicle control, 
followed by three washes with PBS. The IP1 assay was then performed as described above. 
 
ERK1/2 phosphorylation:  The AlphaScreen-based SureFire kit was used for the quantitative 
measurement of phosphorylated ERK1/2 (pERK1/2).  25,000 cells/well were plated into 96-
well plates and incubated overnight at 37°C.  The following day, the growth medium was 
replaced with serum-free (SF) medium for 6h at 37°C, then the cells were stimulated for 5 
min (peak response from time course, data not shown) with various concentrations of ACh or 
FBS (10% v/v) with or without different concentrations of allosteric ligands at 37C. Cells 
were lysed in 100L/well SureFire lysis buffer at -20C overnight. Plates were thawed at 
room temperature and 10L of the cell lysates were transferred to a 384-well Optiplate. In 
reduced lighting conditions, 8.5μl of detection buffer (reaction buffer/activation 
buffer/acceptor beads/donor beads; 60:10:0.3:0.3) was added and plates were incubated for 
1h at 37C. Fluorescence signal was measured using the Envision multilabel plate reader with 
AlphaScreen settings. Data were expressed as a percentage of the pERK1/2 mediated by 10% 
FBS or maximum ACh response. 
 
-arrestin-2 recruitment assays:  FlpInCHO cells were transiently transfected with M1-Rluc8 
and YFP--arrestin-2 as described in cell culture section above. 24h later, they were replated 
into white 96 well Optiplates.  Cells were equilibrated in Hanks’ balanced salt solution for 1h 
at 37C. Coelenterazine h (final concentration 5μM), was added to each well, then 5 min later 
various concentrations of ligands were added. Luminescence and fluorescence readings were 
captured 10 min after coelenterazine h addition using the LUMIstar Omega (BMG LabTech, 
Offenburg, Germany) that allows for the sequential integration of the signals detected at 475 
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± 30 and 535 ± 30 nm using filters with the appropriate band pass. Data are presented as 
BRET ratio, calculated as the ratio of YFP to Rluc8 signals and were normalized to the 
maximum possible BRET ratio elucidated by ACh. 
 
Data analysis:  All data analysis was performed using GraphPad Prism v.7.02. Concentration 
response curves were fitted using a three parameter logistic non-linear regression model to 
derive potency (pEC50) and efficacy (Emax) parameters.  
 
IP1 alkylation experiments were globally fitted to an operational model of agonism (Black 
and Leff, 1983) to determine orthosteric agonist equilibrium dissociation constant (functional 
affinity; KA) and the agonist operational efficacy (τ), which takes both receptor density and 
stimulus-response coupling efficiency into account: 
𝐸 = 𝑏𝑎𝑠𝑎𝑙 +
(𝐸𝑚−𝑏𝑎𝑠𝑎𝑙)𝜏
𝑛[𝐴]𝑛
𝜏𝑛[𝐴]𝑛+([𝐴]+𝐾𝐴)𝑛
                                     (Eqn 1) 
In this model, basal is the response in the presence of vehicle, Em is the maximum possible 
pathway response, [A] is the agonist concentration and n represents the slope of transducer 
function that links occupancy to response.  
 
Concentration-response curves for the functional interactions between orthosteric and 
allosteric ligands were globally fitted to the following simplified operational model of 
allostery and agonism (Aurelio et al., 2009): 
𝐸 = 𝑏𝑎𝑠𝑎𝑙 +  
(𝐸𝑚−𝑏𝑎𝑠𝑎𝑙)([𝐴](𝐾𝐵+𝛼𝛽[𝐵]+𝜏𝐵[𝐵][𝐸𝐶50])
𝑛
[𝐸𝐶50]𝑛(𝐾𝐵+[𝐵])𝑛+([𝐴](𝐾𝐵+𝛼𝛽[𝐵])+𝜏𝐵[𝐵][𝐸𝐶50])𝑛
                               (Eqn 2) 
Where basal is the response in the presence of vehicle, [B] is the concentration of allosteric 
ligand and KB represents its equilibrium dissociation constants. B represents an operational 
measure of allosteric ligand efficacy,  denotes the binding cooperativity between orthosteric 
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and allosteric ligand, whereas β denotes a scaling factor that quantifies the allosteric effect of 
the modulator on orthosteric ligand efficacy. This model assumes that all orthosteric ligands 
are either full agonists at the receptor on both the absence/presence of modulator and/or there 
is no efficacy modulation (i.e., β = 1). As shown in the Results, one or both of these 
assumptions were met with the various orthosteric ligands used, and thus the β parameter was 
constrained to 1. All other parameters are as defined in equation 1. 
 
Also as shown in the Results, the ERK1/2 responses at the M1 mAChR were bell-shaped.  
For the purposes of fitting the allosteric operational model to the data, the points defining the 
decreasing phases of the curves (i.e., those beyond 10μM of agonist) were removed from 
each curve to allow convergence of the allosteric operational model (Eqn 2). 
 
All affinity, potency and cooperativity values were estimated as logarithms (Christopoulos 
1998) and statistical comparisons between values were by one-way analysis of variance with 
either a Neuman-Kewls or Dunnett’s multiple comparison test. A value of p<0.05 was 
considered statistically significant. 
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Results: 
Novel 4-phenylpyridin-2-one and 6-phenylpyrimidin-4-one based compounds are selective 
for the M1 mAChR over other mAChR subtypes.   
Recent work from our laboratory identified a novel series of 4-phenylpyridin-2-one and 6-
phenylpyrimidin-4-one M1 mAChR PAMs (Figure 1A) that represent a different chemical 
scaffold to BQCA and related analogues (Mistry et al., 2016). When assessed for effects on 
the IP1 signalling pathway, our preliminary pharmacological characterization indicated that 
MIPS1674 was an allosteric agonist with minimal PAM activity against ACh, MIPS1745 was 
a “pure” PAM of ACh with no direct allosteric agonism, whereas MIPS1780 behaved as a 
mixed PAM-agonist in modulating ACh function (akin to responses observed with BQCA). 
Thus, the fact that these three PAMs potentially exhibited three different “allosteric 
phenotypes” (Mistry et al., 2016) formed the basis for selecting them for further 
pharmacological evaluation. These compounds were initially tested to ensure they were 
selective for the M1 mAChR over other mAChR subtypes using an ERK1/2 phosphorylation 
assay. Figure 1B-C shows that all PAMs modulated ACh activity at the M1 mAChR, but no 
modulation of ACh-mediated ERK1/2 responses were observed for M2, M3, M4, or M5 
mAChR subtypes with MIPS1674, MIPS1745, MIPS1780 or BQCA (at a concentration 
higher than that needed to see PAM effects at the M1 mAChR), confirming that these 
modulators were selective for the M1 mAChR. It was also noted that ACh displayed a bell-
shaped concentration-response relationship for mediating ERK1/2-phosphorylation at the M1 
mAChR, both in the absence or presence of modulator (Figure 1B). Although the mechanism 
underlying this effect is unknown, it is not due to desensitization or a change in the time to 
peak ACh effect at high concentrations, based on control time course experiments (not 
shown).  
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Determination of M1 mAChR orthosteric agonist functional affinities and intrinsic efficacies 
in stimulating IP1 accumulation.   
The next aim of this study was to investigate the potential for probe dependence of the novel 
allosteric modulators and the contribution of different degrees of intrinsic agonist efficacy to 
the phenomenon. mAChR agonists of variable efficacies were selected to use as orthosteric 
probes. Specifically, the endogenous agonist, ACh, was chosen as this represents the 
physiologically relevant mAChR neurotransmitter against which all putative allosteric 
ligands need to be tested. Oxotremorine-M (Oxo-M) was chosen, as this is commonly used as 
a high efficacy mAChR agonist in numerous in vitro and in vivo studies (e.g., Valant et al., 
2012).  Iperoxo (Ixo) was chosen as it remains the highest efficacy mAChR agonist identified 
to date (Langmead and Christopoulos 2013; Schrage et al., 2013), while Xanomeline (Xan) 
was chosen because it is a partial agonist, has a functional preference for M1 and M4 
mAChRs over other mAChR subtypes, and had progressed into clinical trials on the basis of 
this selectivity (see Introduction).  
 
Initially, the affinities and intrinsic efficacies of the orthosteric agonists were characterised 
using an assay of M1 mAChR-mediated IP1 accumulation, a classic signalling pathway 
downstream of activation of Gq/11-linked receptors. All orthosteric agonists increased IP1 
accumulation in our FlpInCHO-hM1 cell line in a concentration-dependent manner. ACh, Ixo 
and Oxo-M were all full agonists in this assay, whereas, Xan was a weak partial agonist (with 
an Emax approx. 30% of that observed for ACh; Table 1).  The functional affinities (pKA) and 
operational efficacies (τ) of the othosteric probes were also determined at the M1 mAChR by 
treating the cells with the irreversible alkylating agent, phenoxybenzamine (PBZ), to occlude 
the orthosteric site (Furchgott 1966), thus reducing the number of accessible M1 binding sites 
in the FlpInCHO-hM1 cells. Increasing levels of alkylation of the orthosteric site by PBZ 
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substantially reduced the Emax of all agonists with minimal effects on the potency of ACh, 
Oxo-M and Xan (Figure 2). Small, albeit significant (p < 0.05) effects were observed on the 
potency of Ixo, where a 0.5-1 log unit shift was observed when treated with the higher 
concentrations of PBZ (1μM and 10μM, respectively). Overall, this suggests that this system 
has a low level of receptor reserve for this pathway in our cell line. The family of curves for 
each agonist was globally fitted to an operational model of agonism (Eqn 1), with the 
efficacy parameter, τ, allowed to vary for each curve (since τ is determined by receptor 
density) but all other parameters constrained to be shared. The resulting agonist functional 
affinity values, determined as equilibrium dissociation constants (KA), and the τ values for the 
control curve (absence of PBZ) are listed in Table 1, which confirms a rank order of 
efficacies of Ixo ( = 10.7) > Oxo-M ( = 4.6) > ACh ( = 3.6) >> Xan ( = 0.5).  In addition 
to the efficacy estimates, the agonist KA values revealed that Xan and Ixo had significantly 
higher affinities for the M1 mAChR than ACh or Oxo-M (p < 0.05, Table 1). 
 
BQCA exhibits probe dependence with different orthosteric agonists at the M1 mAChR.   
As outlined in the Introduction, the simplest mechanism to explain probe dependence is the 
classic two-state MWC model.  This model predicts that the effect of a PAM is to positively 
modulate the activity of an orthosteric agonist but negatively modulate the activity of an 
orthosteric antagonist (inverse agonist) in a manner that tracks with the intrinsic efficacy of 
the orthosteric ligand, i.e., higher efficacy agonists will be potentiated to a greater degree 
than lower efficacy agonists; the model does not predict pathway-biased modulation without 
incorporation of additional receptor states (Canals et al., 2012; Christopoulos 2014; Ehlert 
and Griffin, 2014). Thus, the next series of experiments investigated the potential for probe 
dependence between different agonists and the prototypical M1 mAChR PAM, BQCA. 
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Figure 3 shows the results of interaction experiments between increasing concentrations of 
BQCA and each of the orthosteric agonists ACh, Oxo-M, Ixo or Xan in the IP1 accumulation 
assay. BQCA did not affect the Emax of any orthosteric agonist tested, but did potentiate the 
effects of ACh on IP1 signal transduction. The data were globally fitted to an operational 
model of allostery (Eqn 2), where the pKB of the allosteric modulator, BQCA, was 
constrained to 4.78 (Mistry et al., 2016).  This constraint was used to aid model convergence, 
and was selected because it is the binding affinity value determined from full interaction 
equilibrium binding assays between ACh, BQCA and 
3
H-NMS in the same cell line used for 
this study (Mistry et al., 2016). The resulting parameter values are listed in Table 2.  From 
these experiments and resulting analysis, two important findings were made.  First, the 
degree of potentiation of each agonist by BQCA was variable (α values), clearly indicating 
probe dependence. Second, it was of note that the allosteric modulation was manifested only 
on the potency of each agonist (i.e., changing the EC50 and not on the Emax).  Given that the 
prior alkylation studies (Figure 2, Table 1) confirmed that this assay has minimal receptor 
reserve, any potential allosteric effects on agonist signalling efficacy would have been 
revealed as increases in the Emax, at least for the lower efficacy agonists. The fact that this 
was not observed in any instance indicates that BQCA modulates only the affinity of the 
orthosteric agonists, not their efficacy. As such, the co-operativity estimates (αβ) from the 
operational model analysis are measures of “pure” affinity modulation (α). 
 
As summarized in Table 2 and Figure 3, BQCA potentiated ACh (αACh = 40) and Ixo (αIxo = 
25) to the greatest extent; Oxo-M (αOxoM = 10) was potentiated to a lesser extent, although 
realistically these differences in potentiation were marginal, showing only a four-fold 
difference at most. BQCA showed no modulation, i.e., was a neutral allosteric ligand (NAL), 
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with respect to the weakest agonist, Xan. On its own, BQCA showed very little to no intrinsic 
efficacy (τB = 0.2-0.8), confirming previous findings (Yeatman et al., 2014).  
 
Effects of novel M1 mAChR PAMs on ACh-mediated IP1 accumulation 
We next investigated the effects of each of the two 4-phenylpyridin-2-one-based (MIPS1674 
and MIPS1745) and the 6-phenylpyrimidin-4-one-based (MIPS1780) analogues on IP1 
accumulation mediated by the endogenous agonist, ACh (Figure 4). As observed with 
BQCA, each of the novel M1 mAChR PAMs enhanced only the potency of ACh. As above, 
the allosteric modulator affinity values were constrained to the binding affinity values (pKB) 
for MIPS1674 (4.45), MIPS1745 (4.50) and MIPS1780 (4.88) that were previously 
determined by Mistry et al. (2016) in full binding interaction studies in the same cell line as 
used in this study. The resulting co-operativity estimates (αACh) are shown in Table 2 and 
Figure 6.  The ACh response was potentiated to a greater extent by MIPS1780 (αACh = 302) 
and MIPS1745 (αACh = 129) than BQCA (αACh = 40), whereas MIPS1674 (αACh = 11) clearly 
showed a substantially lower degree of potentiation.  Interestingly, we also noted a number of 
differences in the behaviour of the novel PAMs compared to our initial preliminary 
characterization (Mistry et al., 2016).  For instance, MIPS1674 showed modest modulatory 
effects on ACh but little to no direct allosteric agonism.  MIPS1745 was not a “pure” PAM as 
originally described by Mistry et al., (2016) but rather, a PAM-agonist (B = 1.2) like 
MIPS1780 (B = 5.9). Although the same cellular background was used for both the current 
study and that of Mistry et al. (2016), the IP1 accumulation assay protocol was performed 
under different conditions (adherent vs suspended cells), which may account for the 
differences observed. 
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Investigation of mechanisms of probe dependence mediated by MIPS1674, MIPS1780 and 
MIPS1745 with different agonists at the M1 mAChR. 
To determine whether the novel PAMs exhibit probe dependence, the interaction experiments 
were extended to include the effects of other mAChR agonists on IP1 accumulation. As 
observed with BQCA, no effect of the novel PAMs on the maximal response of the various 
agonists used in this study was detected (Figure 5), again suggesting that any allosteric 
modulation by the novel M1 mAChR PAMs is manifested at the level of agonist binding 
affinity only.  Subsequent analysis of these data by an operational model of allostery (Eqn 2) 
provided co-operativity estimates for individual modulators with each agonist (Table 2; 
summarized Figure 6B-D).  MIPS1674 potentiated the ACh response (α = 11) to a greater 
extent than Oxo-M (α = 5) and significantly more than that seen with Ixo (α = 3), suggesting 
that this modulator exhibits probe dependence, modulating the endogenous agonist ACh to a 
greater extent than the higher potency agonist Ixo. MIPS1745 and MIPS1780 behaved like 
BQCA, in that they potentiated ACh, Ixo and Oxo-M to similar extents (Figure 6).  Xan was 
weakly modulated (α = 19) by the most robust PAM, MIPS1780, although the co-operativity 
estimate was associated with a larger error than for the other agonists. No modulation of the 
Xan response was observed with any of the other allosteric modulators tested, again 
consistent with a NAL effect. Nonetheless, the overall findings are broadly consistent with 
those seen with BQCA, that is, the higher efficacy agonists were modulated to a greater 
extent than the lowest efficacy agonist (Xan).  For a weak PAM, i.e., MIPS1674, the overall 
degree of positive modulation was low irrespective of the agonist (Figure 6B), whereas for 
the most robust PAMs, i.e., MIPS1780 and MIPS1745, the magnitude of the positive 
cooperativity noted with ACh, Oxo-M or Ixo (Figure 6) was in the range observed with the 
prototypical PAM, BQCA. 
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Novel M1 PAMs show minimal evidence of biased modulation 
It is not uncommon to see different overall degrees of functional PAM effects of GPCR 
modulators in cell-based assays. Although this may be taken as presumptive evidence of 
“pathway biased modulation”, a simpler explanation is that assays characterized by stronger 
stimulus-response coupling (e.g., more amplified responses), may be more prone to 
manifesting stronger PAM effects due to the potential greater sensitivity of PAM-agonism 
being unmasked in such assays (Keov et al., 2011). It is only when this property is not a 
contributor that true pathway bias can be considered. Previously, BQCA showed no bias, 
relative to ACh, when tested against carbachol in a range of signalling assays (Canals et al., 
2012; Yeatman et al., 2014).  To confirm this general effect we used the endogenous agonist, 
ACh, and the PAM, BQCA, as comparators for the effects of the new chemotypes. We first 
examined the effect of BQCA on the endogenous agonist, ACh, toward 3 signalling 
pathways; ERK1/2 phosphorylation as a representative of an efficiently coupled pathway; IP1 
accumulation and β-arrestin-2 recruitment (βarr2) as weakly coupled pathways.  In Figure 
7A-C, the family of curves were globally fitted to the operational model of allostery (Eqn 2), 
constraining the pKB values to the binding affinity values determined by Mistry et al., (2016), 
as described above, and with the resulting parameters shown in Table 3.  The rank order of 
co-operativity for the pathways was ERK1/2 (α = 871) >> IP1 (α = 40) ≥ βarr2 (α = 23). 
 
The novel 4-phenylpyridin-2-ones and 6-phenylpyrimidin-4-one were also tested on the same 
three pathways and the data sets were analysed in the same manner as BQCA (described 
above). MIPS1745 and MIPS1780 had the greatest efficacy (τB) toward the more amplified 
ERK1/2 pathway and lower efficacy toward the IP1 and βarr2 pathways (Figure 8H-I, Figure 
9). MIPS1780 strongly potentiated (αERK = 550; αIP1 = 309; αβarr2 = 229) all pathways. A 
similar pattern of potentiation was seen with MIPS1745 (αERK = 380; αIP1 = 129; αβarr2 = 42) 
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(Table 3, Figure 8 and Figure 9). The rank order of co-operativity was ERK1/2>IP1>βarr2, 
thus as observed with BQCA, MIPS1745 and MIPS1780 were PAMs toward all pathways, 
and the potentiation of the responses tracked with stimulus coupling.  
 
When the MIPS1674 data were analysed using the operational model of allostery (Eqn 2), it 
did not appear to modulate βarr2 recruitment, but did weakly modulate the other signalling 
pathways. As shown in Figure 8, Figure 9 and Table 3, MIPS1674 had weak efficacy toward 
the ERK1/2 (τB = 1.4) pathway and no efficacy for the IP1 or βarr2 pathways.  MIPS1674 
weakly modulated ACh activity toward ERK1/2 and IP1, with a rank order of co-operativity 
of IP1 (α = 12) > ERK1/2 (α = 4).  By visual inspection of the concentration response curves, 
MIPS1674 acted as a “pure” PAM towards IP1, is an allosteric agonist with minimal PAM 
activity toward ERK1/2, and was a NAL toward βarr2. Although, these results may suggest 
that MIPS1674 has the potential to be a biased modulator at the M1 mAChR, a more 
parsimonious explanation is that the low level of receptor expression and differences in 
stimulus-response coupling the IP1 and β-arrestin recruitment pathway resulted in an 
insufficient response window to reveal any potentiation of the ACh β-arrestin recruitment 
response, particularly since MIPS1674 was the least effective PAM of the new series.  
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Discussion: 
The discovery of BQCA ushered in a new era of drug discovery for the M1 mAChR, 
particularly with regards to novel potential modalities for treatment of cognitive deficits (Ma 
et al., 2009; Davie et al., 2013). Subsequent detailed pharmacological characterization of 
BQCA also revealed key features consistent with the simplest mechanism of receptor 
allostery, namely the two-state MWC model (Canals et al., 2012), and thus provided a guide 
for the subsequent pharmacological assessment of novel allosteric modulators at both 
mAChRs and other GPCRs. This is relevant to the current study, which investigated novel 
PAMs chemically distinct from BQCA. Preliminary findings with the 4-phenylpyridin-2-ones 
and 6-phenyl-4-ones suggested that they may have diverse pharmacological phenotypes, 
reflective of more complex, and potentially biased, allosteric behaviours (Mistry et al., 2016).  
The main findings of this study indicate that the novel M1 mAChR PAMs display probe 
dependence at the M1 mAChR but minimal evidence of biased modulation. These findings 
have implications for future elaboration of this new chemical series, with an ultimate aim 
towards producing molecules that are more tractable to “drug-like” behaviour than BQCA. 
 
As indicated previously, the key prediction of a two-state MWC model is that the degree of 
allosteric modulation will “track” with the efficacy of the orthosteric probe, i.e., if an 
allosteric ligand prefers an active receptor state, it follows that: (i) it will be a PAM of 
agonists and a NAM (negative allosteric modulator) of inverse agonists (and vice versa for 
modulators that prefer the inactive state); (ii) that higher efficacy agonists will be potentiated 
by PAMs to a greater extent than lower efficacy agonists; (iii), there should be no pathway-
biased modulation (Canals et al., 2011; 2012). Any divergence from this behaviour could 
suggest a more complex mode of action involving multiple receptor states. However, since 
cellular stimulus-response coupling will have an effect on observed agonism (Keov et al., 
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2011), it is vital to account for this property and, where possible, apply approaches that 
divorce the host system-dependence of allostery and agonism from the underlying molecular 
parameters that govern these phenomena. The different degree of maximal agonist 
responsiveness observed in the IP1 accumulation assays indicated that our recombinant cell 
line likely exhibited a very low receptor reserve, which was confirmed by receptor alkylation 
experiments and application of an operational model of agonism. However, it should be noted 
that a detailed analysis of the predictions of the MWC model in operational terms by Ehlert 
and Griffin (2014) found that the only aspects of the stimulus-response transduction 
mechanism that should affect observed modulation (αβ values) are receptor-proximal events, 
e.g., receptor or transducer stoichiometry. Moreover, low efficacy agonists may be expected 
to show changes in the maximal response (Ehlert and Griffin, 2014), which was not observed 
in our current study (e.g., with Xan). It is possible that this reflects a divergence from an 
MWC mechanism or, more parsimoniously, that Xan selects for a very low activity state such 
that any effects on its signaling efficacy simply cannot be observed over the concentration 
range of PAMs utilized in our study. 
 
The low receptor reserve of the FlpInCHO-hM1 cell system proved both advantageous and, to 
some extent, disadvantageous depending on the question that was asked.  An advantage of 
the low receptor reserve system is that the lack of effect of BQCA and the novel PAMs on 
agonist Emax, while modulating potency, could only be explained if the modulators mediated 
their effects purely through changing agonist affinity, as efficacy effects would manifest as a 
change in Emax, particularly for Xan. This allowed the application of a simplified operational 
model of allostery that quantified the global cooperativity of the PAMs (Aurelio et al., 2009). 
Although differences were observed in the behaviours and operational model parameter 
estimates in our IP1 accumulation studies versus those performed by Mistry et al. (2016), this 
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likely reflected variances in IP1 assay protocol, as well as potential variability in cell 
background due to cell passage. Irrespective, our analysis suggested that all novel PAMs, like 
BQCA, tended to potentiate higher efficacy agonists to a greater extent than the low efficacy 
agonist, Xan.  
 
A possible disadvantage of the low receptor reserve displayed by our cell line was evident in 
the studies of allosteric modulation between different pathways linked to M1 mAChR 
activation. Ideally, the choice of pathways was designed to reflect events that are generally 
considered substantially proximal (e.g., β-arrestin 2 recruitment) or substantially downstream 
(e.g., pERK1/2) from receptor activation, with IP1 accumulation representing a pathway that 
would display a degree of stimulus-response coupling somewhere between the two 
(Lanzafame et al., 2003; Canals et al., 2012; Abdul-Ridha et al., 2014). This, in turn, would 
allow for a clear delineation of whether the modulation between a given agonist-modulator 
pair tracked with the degree of stimulus-response coupling or differed.  The former scenario 
was generally the case when comparing the effects of the PAMs on ACh-mediated pERK1/2 
to either β-arrestin 2 recruitment or IP1 accumulation, but more equivocal when comparing 
ACh-mediated β-arrestin 2 recruitment to IP1 accumulation.  However, if the degree of 
receptor coupling efficiency to the IP1 pathway and β-arrestin 2 recruitment pathways was 
similar, due to low receptor reserve, then the MWC model would predict similar degrees of 
potentiation at each pathway, and it is thus not surprising that the PAM effects on ACh at β-
arrestin 2 recruitment or IP1 accumulation did not display the degree of separation seen when 
compared to the pERK1/2 assays. 
 
It is now established that allosteric ligands have the potential to engender multiple 
biologically active GPCR states (Kenakin et al., 2012; Davey et al., 2012; Wislar et al., 
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2007). As a consequence, deviations from simple MWC-governed allosteric behaviour in 
terms of probe dependence and pathway bias have been observed at multiple GPCRs, 
emphasising the importance of routinely investigating these therapeutically relevant 
paradigms whenever characterising novel ligands (Christopoulos 2014; Price et al., 2005; 
Valant et al., 2012). For example, at the M2 mAChR, the allosteric modulator, LY2033298, 
positively modulates the binding affinity of multiple orthosteric agonists, but has either 
positive or negative allosteric effects on the signalling efficacy and signalling pathway of the 
same agonists. Thus, functionally, LY2033298 is a PAM of Oxo-M, a NAL of ACh, and a 
NAM of Xan (Valant et al., 2012). This type of probe dependence cannot be reconciled 
within a two-state mechanism, and is clearly suggestive of biased modulation involving 
multiple receptor active states (Christopoulos 2014).  Given that surrogate orthosteric probes 
are often used preclinically in vitro or in vivo, due to the metabolic instability of the 
endogenous GPCR agonist (Leach et al., 2010), or that multiple endogenous ligands and their 
metabolites exist for a single GPCR (van der Westhuizen et al., 2015, Wootten et al., 2012), a 
lack of appreciation of the differences underlying probe dependence as a function of intrinsic 
efficacy (i.e., simple two-state MWC model) or probe dependence as a function of different 
conformational states (i.e., biased modulation), can lead to misinterpretation of preclinical 
data and thus inappropriate selection of potential allosteric drug candidates for further 
optimization and development. 
 
In conclusion, despite possessing a chemically distinct scaffold, the similar molecular 
fingerprints of the 4-phenylpyridine-2-one and 6-phenylpyrimidin-4-one PAMs to that of 
BQCA suggests a similar molecular mechanism of action, and is consistent with a common 
binding site. This site is proposed to overlap with the “common” allosteric binding pocket 
located in the extracellular vestibule of mAChRs. However, additional structure-function 
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analyses are required to confirm this hypothesis. Perhaps more importantly, the availability of 
a novel chemical scaffold of known molecular properties could facilitate the development of 
superior M1 mAChR PAMs with a higher likelihood of clinical translation than first 
generation compounds exemplified by BQCA. 
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Legends for Figures: 
 
Figure 1.  Novel 4-phenylpyridine-2-ones and 6-phenylpyrimidin-4-one selectively 
modulate the M1 mAChR over other mAChR subtypes. (A) The structurally novel M1 
mAChR PAMs selected for this study, MIPS1674, MIPS1745 and MIPS1780 (previously 
published as compounds “14, 17 and 29”, respectively, by Mistry et al., (2016)). They were 
compared to the reference modulator, BQCA.  (B) The 4-pheylpyridine-2-ones and 6-
phenylpyrimidin-4-one based analogs all showed intrinsic efficacy and potentiation of the 
ERK1/2 response at the M1 mAChR.  (C) The novel PAMs or BQCA did not modulate ACh-
mediated ERK1/2 phosphorylation at the M2, M3, M4 or M5 mAChR subtypes, when tested at 
a concentration of 10µM. Data are mean±SEM of four independent experiments performed 
with duplicate repeats.  
 
Figure 2.  Receptor alkylation assays identify low receptor reserve in FlpInCHO-M1 cell 
lines. FlpInCHO-M1 cells were pre-treated with different concentrations of 
phenoxybenzamine (PBZ) for 30 min, followed by extensive washout to reduce receptor 
reserve.  Cells were then stimulated for 60 min with increasing concentrations of (A) ACh, 
(B) Ixo, (C) Oxo-M or (D) Xan. Decreases in Emax and minimal changes in EC50 values were 
observed with all orthosteric ligands, suggesting that the FlpInCHO-M1 cell line used in this 
study expressed low levels of M1 mAChRs. Data are mean±SEM of 6 independent 
experiments with repeats in duplicate.  Fitted curves shown are global analysis based on the 
operational model (Eqn 1). 
 
Figure 3.  BQCA displays probe dependence with different agonists in IP1 accumulation. 
Interaction between (A) ACh, (B) Ixo, (C) Oxo-M or (D) Xan with or without increasing 
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concentrations of BQCA were performed in FlpInCHO-hM1 cells at 37°C for 1h. Data are 
expressed as a percentage of the maximal ACh response and are the mean ± SEM of 6-15 
independent experiments performed in duplicate. Fitted curves are from global analysis of 
datasets according to an operational model of allosterism (Eqn 2) with parameter estimates 
shown in Table 2.  
 
Figure 4.  The structurally novel PAMs differentially modulate ACh-induced IP1 
accumulation at the M1 mAChR. Experiments were performed on FlpInCHO-hM1 cells, 
using increasing concentrations of ACh with or without increasing concentrations of (A) 
MIPS1674, (B) MIPS1745 or (C) MIPS1780 at 37°C for 1h. Data are expressed as a 
percentage of maximum ACh response and are the mean ± SEM of 15 independent 
experiments performed in duplicate. Fitted curves are from global analysis of datasets 
according to an operational model of allosterism (Eqn 2), with parameter estimates shown in 
Table 2.  
 
Figure 5.  The novel M1 PAMs modulate IP1 accumulation with different orthosteric 
probes to different extents. IP1 accumulation assays in FlpInCHO-hM1 cells were performed 
with increasing concentrations of different orthosteric probes (A, D, G) Ixo, (B, E, H) Oxo-M 
or (C, F, I) Xan at 37°C for 1h. Allosteric modulators (A, B, C) MIPS1674, (D, E, F) 
MIPS1745 and (G, H, I) MIPS1780 were co-added with the orthosteric ligands for 1h at 
37°C. Curves represent the best global fit to the allosteric operational model (Eqn 2) with the 
resulting parameters found in Table 2. Data are mean±SEM of 6 independent experiments 
with repeats in duplicate. 
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Figure 6.  Probe-dependence between orthosteric agonists and allosteric modulators.  Co-
operativity estimates (log ) were derived from global analysis of data sets in Figures 4 and 5 
and resulting parameters are reported in Table 2. (A) BQCA potentiated ACh and Ixo more 
than Oxo-M. (B) MIPS1674 potentiated ACh to a greater extent than Ixo or Oxo-M. (C) 
MIPS1745 potentiated ACh, Ixo and Oxo-M to similar extents. (D) MIPS1780 potentiated 
ACh, Ixo and Oxo-M to a greater extent than Xan. Data are mean±SEM of 6-15 independent 
experiments with repeats in duplicate.  Data were analyzed by One-way ANOVA with a 
Neuman-Kewls multiple comparison test, where *p<0.05 was considered significantly 
different.  
 
Figure 7.  BQCA potentiates ACh at three distinct signaling pathways. FlpInCHO-hM1 
cells were stimulated with different concentrations of ACh and responses to three different 
signaling pathways were measured. β-arrestin 2 recruitment and ERK1/2 responses were 
measured after 5 min of stimulation, whereas IP1 accumulation was measured after 1h. 
BQCA potentiates ACh signaling toward (A) β-arrestin 2 recruitment, (B) IP1 accumulation 
and (C) ERK1/2 phosphorylation. Data were fitted with the allosteric operational model with 
the resulting parameters reported in Table 3. Data are mean±SEM of 6-15 independent 
experiments with repeats in duplicate. 
 
Figure 8. Minimal evidence for pathway biased modulation by the novel M1 PAM 
scaffolds.  FlpInCHO-hM1 cells were stimulated with different concentrations of ACh and 
responses to three different signaling pathways were measured. β-arrestin 2 recruitment and 
ERK1/2 responses were measured after 5 min of stimulation and IP1 accumulation was 
measured after 1h. MIPS1674 acted as a neutral allosteric ligand toward (A) β-arrestin 2 
recruitment, as a “pure” PAM for (D) IP1 accumulation and an allosteric agonist with 
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minimal PAM activity towards (G) ERK1/2 signalling. MIPS1745 and MIPS1780 were 
PAM-agonists toward (B and C) β-arrestin 2 recruitment, (E and F) IP1 accumulation and (H 
and I) ERK1/2 phosphorylation, suggesting that they are not biased modulators of ACh at the 
M1 mAChR. Fitted curves are from global analysis of datasets according to an operational 
model of allosterism (Eqn 2), with parameter estimates shown in Table 3. Data are 
mean±SEM of 4-15 independent experiments with repeats in duplicate. 
 
Figure 9.  Comparison of the efficacy and co-operativity estimates of the 4-phenylpyridin-
2-one and 6-phenylpyrimidin-4-one PAMs toward three signaling pathways. FlpInCHO-
hM1 cells were stimulated with different concentrations of ACh and responses to three 
different signaling pathways were measured. ERK1/2 phosphorylation and β-arrestin 2 
recruitment were measured after 5 min stimulation at 37°C. IP1 accumulation was measured 
following stimulation with ligands for 1h at 37°C.  Data from interaction experiments 
between different concentrations of ACh and PAMs were fitted to the operational model of 
allosterism (Eqn 2) and the (A, C, E, G) efficacy (log τB) and (B, D, F, H) cooperativity (log 
α) parameters were obtained (also shown in Table 3). Data are mean±SEM of 4-8 
independent experiments with repeats in duplicate. Data were analysed by one-way ANOVA, 
with Neuman-Kewls multiple comparisons tests, where *p<0.05 was considered to be 
significantly different. 
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Tables: 
 
Table 1. Empirical and operational model parameter estimates for the orthosteric 
ligands in mediating the IP1 accumulation via activation of the M1 mAChR in 
FlpInCHO-hM1 cells. Concentration response curves for orthosteric ligands were 
established in the absence or presence of PBZ pretreatment (followed by extensive washout). 
Data were fitted using the operational model (Eqn 1) to determine the functional affinity 
(pKA) and operational efficacy (logτ) values. Parameter values are the mean±SEM of 8 
independent experiments with repeats in duplicate. Data were analyzed by one way ANOVA 
(with alpha = 0.01) using a Dunnett’s multiple comparisons test, where *p<0.05 was 
considered to be significantly different to those of the endogenous agonist ACh. 
Ligand pEC50
a
 Emax
b
 pKA
c
 LogτA
d
 τA
e
 
ACh 5.79±0.07 99.7±2.9 5.26±0.23 0.55±0.29 3.6 
Ixo 7.97±0.09* 101.3±3.3 6.99±0.17* 1.03±0.23* 10.7 
Oxo-M 6.08±0.13 90.3±4.8 5.35±0.28 0.66±0.40* 4.6 
Xan 6.96±0.21* 29.8±2.7* 6.48±0.51* -0.31±1.3* 0.5 
a
Negative logarithm of the EC50 value of the vehicle-pretreated control curve. 
b
Maximal agonist response under the vehicle-pretreated conditions, relative to ACh 
c
Negative logarithm of the functional affinity value constant KA, derived using Eqn 1. 
d
Logarithm of the operational efficacy parameter for the orthosteric agonist in the absence of 
PBZ-pretreatment derived using Eqn 1. 
e
Antilogarithm of the operational efficacy parameter. 
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Table 2. Allosteric model estimates for 4-phenylpyridine-2-ones and 6-phenylpyrimidin-4-ones at the M1 mAChR with different mAChR 
othosteric agonists for IP1 accumulation in FlpInCHO-hM1 cells. Orthosteric agonist concentration-response curve families in the absence 
or presence of each modulator were analysed using Eqn 2, with the logKB constrained to the value derived previously in Mistry et al., (2016).  
Data are the mean±SEM of 4-15 independent experiments with repeats in duplicate. Data were analyzed by one-way ANOVA with a Neuman-
Kewls multiple comparison test, where *p<0.05 was considered to be significantly different to ACh. 
 BQCA MIPS1674 MIPS1745 MIPS1780 
 logα
a
 (α)b logτB
c
 (τB)
d
 logα
a
 (α)b logτB
c
 (τB)
d
 logα
a
 (α)b logτB
c
 (τB)
d
 logα
a
 (α)b logτB
c
 (τB)
d
 
ACh 1.60±0.09 (40) -0.46±0.12 (0.3) 1.06±0.08 (11) -3 (0) 2.11±0.12 (129) 0.08±0.05 (1) 2.48±0.14 (302) 0.77±0.04 (6) 
Ixo 1.40±0.14 (25) -0.09±0.10 (0.8) 0.44±0.17* (3) -3 (0) 1.86±0.17 (72) 0.10±0.07 (1) 2.22±0.17 (166) 0.87±0.05 (7) 
Oxo-M 0.99±0.18* (10) -0.75±0.33 (0.2) 0.69±0.15 (5) -3 (0) 1.86±0.22 (72) -0.14±0.11 (0.7) 1.98±0.17 (95) 0.78±0.04 (6) 
Xan NM  NM  NM  NM  1 (129) 0.38±0.05* (2) 1.29±0.62 (19) 1.16±0.07* (14) 
NM; no modulation (NAL effect) 
a
Logarithm of the functional cooperativity estimate between the orthosteric ligand and allosteric modulator derived using Eqn 2. 
b
Antilogarithm of the functional cooperativity estimate between the orthosteric ligand and allosteric modulator  
c
Logarithm of the operational efficacy parameter of the allosteric modulator derived using Eqn 2. Where no intrinsic efficacy of the allosteric 
modulator was observed, the τB values were constrained to -3 (τ = 0.001) to aid model convergence. 
d
Antilogarithmhm of the operational efficacy parameter of the allosteric modulator  
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Table 3. ACh potency and allosteric model parameter estimates for interaction with 4-phenylpyridine-2-ones and 6-phenylpyrimidin-4-
ones at the M1 mAChR for three different signaling pathways in FlpInCHO-hM1 cells.  For allosteric model analysis, ACh concentration-
response curves, established in the absence or presence of each modulator, were fitted to Eqn 3. The initial increase in ERK1/2 phosphorylation 
data was used (with the decreasing phase removed) for the purpose of the ERK1/2 analysis.  Data are the mean±SEM of 4-15 independent 
experiments with repeats in duplicate. Data were analyzed by one-way ANOVA with a Newman-Kewls post hoc test to compare all groups. 
Results of the statistical tests are shown in Figure 9. 
 BQCA MIPS1674 MIPS1745 MIPS1780 
 ERK1/2 IP1 βarr2 ERK1/2 IP1 βarr2 ERK1/2 IP1 βarr2 ERK1/2 IP1 βarr2 
pEC50
a
 7.19±0.13 5.73±0.05 5.50±0.07 7.54±0.11 5.81±0.08 5.17±0.07 7.16±0.08 5.67±0.08 5.28±0.13 7.24±0.08 5.47±0.09 5.18±0.12 
pKB
b
 4.78 4.78 4.78 4.45 4.45 4.45 4.50 4.50 4.50 4.88 4.88 4.88 
Logα
c
 2.94±0.20 1.60±0.09 1.37±0.12 0.64±0.46 1.06±0.08 NM 2.58±0.25 2.11±0.12 1.62±0.20 2.74±0.25 2.49±0.15 2.36±0.15 
LogτB
d
 1.18±0.09 -0.46±0.12 -0.31±0.12 0.14±0.14 -3 NM 1.15±0.09 0.07±0.05 -0.36±0.14 1.75±0.06 0.78±0.05 0.14±0.07 
NM; no modulation (NAL effect) 
a
Negative logarithm of the ACh EC50 value 
b
Negative logarithm of the binding affinity value determined previously in Mistry et al., (2016), and constrained as a constant in the current 
analysis. 
c
Logarithm of the cooperativity between ACh and the allosteric modulator, derived using Eqn 2. 
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d
Logarithm of the operational efficacy parameter of the allosteric modulator, derived using Eqn 2; or constrained to -3 where no intrinsic 
efficacy of the allosteric modulator was observed. 
  
 
  
  
 
 
  
  
 
  
  
 
 
  
  
  
  
 
